Fed. Circ. Urged To Preserve Novartis' Bench Trial Loss

By Theresa Schliep ( December 22, 2025, 5:12 PM EST) -- MSN Pharmaceuticals has pushed back against Novartis' efforts to save its case accusing the generic drugmaker of infringing a patent covering the blockbuster cardiovascular drug Entresto, telling the Federal Circuit that the appeal "reveals no district court error, just Novartis' poor litigation strategy."...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login